Alzheimer’s disease (AD) is an irreversible and neurodegenerative disease that slowly impairs memory and neurocognitive function, but the etiology of AD is still unclear. With the explosive growth of electronic health data, the application of artificial intelligence (AI) in the healthcare setting provides excellent potential for exploring etiology and personalized treatment approaches, and improving the disease’s diagnostic and prognostic outcome. This paper first briefly introduces AI technologies and applications in medicine, and then presents a comprehensive review of AI in AD. In simple, it includes etiology discovery based on genetic data, computer-aided diagnosis (CAD), computer-aided prognosis (CAP) of AD using multi-modality data (genetic, neuroimaging and linguistic data), and pharmacological or non-pharmacological approaches for treating AD. Later, some popular publicly available AD datasets are introduced, which are important for advancing AI technologies in AD analysis. Finally, core research challenges and future research directions are discussed.

Alzheimer’s disease (AD) is the most prevalent type of dementia, and its neuropathology is characterized by the deposition of insoluble β-amyloid (Aβ) peptides, intracellular neurofibrillary tangles, amyloid angiopathy, age-related brain atrophy, synaptic pathology, white matter rarefaction, granulovacuolar degeneration, neuron loss, and neuroinflammation. Although much is known about the neurobiology of AD, very few conventional therapies are available to arrest or slow the disease. There is an urgent need for novel therapeutic approaches for AD. AD subjects have significantly fewer viable precursor cells in the hippocampus compared with age-matched healthy control subjects. However, the viable precursor cells that remain in AD and age-matched healthy control brain specimens can be induced to differentiate. To facilitate or mimic the natural compensatory effect in AD, cell therapy, including endogenous and exogenous stem cells, has been considered in AD. In this review, we focus on the history and development of cell therapy in AD, and consider the role of cell therapy as a potential treatment for AD.

Stroke is the second most common single cause of death worldwide, with over five million deaths per year globally. So far, conventional therapy has failed to restore neurological function poststroke. Neurorestorative strategy has provided therapeutic benefit for the treatment of stroke. This review outlines the clinical advances, in which cell-based neurorestorative strategies offer the broadest range of potential treatments for stroke.

Alzheimer’s disease (AD) is the most prevalent type of dementia, and its neuropathology is characterized by the deposition of insoluble β-amyloid peptides and intracellular neurofibrillary tangles and the loss of diverse neurons. Although much is known about the neurobiology of AD, few treatments are available to arrest or slow the illness. There is an urgent need for novel therapeutic approaches for AD. We reviewed the recent improvements in the neurorastorlogy strategies for AD, including medicine, bioengineering and neuromodulation and clinical cell therapy. We emphasized that cell therapy may be an promising treatment for AD.